Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (202)	12/11/2000 11:22:14 PM
From: Pseudo Biologist	Read Replies (4) \| Respond to of 1784

tuck, thanks this looks very cool. I understand that the fellow mentioned there, Reudi Aebersold, is the guru of mass spec proteomics. Here is "Fool" take on an aspect of trickle, the ever popular "drug discovery platform for hire" model, that wisely has not been emphasized here (RSTA talk excepted -g-) fool.com I am not sure Tom is as coherent as he should be, but the point is well taken that without the prospects of a drug, it is hard to see how some of the companies in this space can justify their valuations. Putting MLNM and HGSI in the list is kind of silly at this stage. Anyway, hope Rick does not excommunicate me for linking to the Fool -g- PB